Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH
Authors
Keywords
Cytokeratin 18, Nonalcoholic liver disease, Test reliability, Liver fibrosis, Apoptosis, Biomarker
Journal
DIGESTIVE DISEASES AND SCIENCES
Volume 61, Issue 3, Pages 905-912
Publisher
Springer Nature
Online
2015-10-14
DOI
10.1007/s10620-015-3916-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
- (2015) Stuart McPherson et al. JOURNAL OF HEPATOLOGY
- Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis – A Comparison with Routine Biochemical Markers
- (2014) Wah-Kheong Chan et al. PLoS One
- A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
- (2013) Raluca Pais et al. JOURNAL OF HEPATOLOGY
- Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease
- (2013) Kenneth Cusi et al. JOURNAL OF HEPATOLOGY
- Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers
- (2012) J. Shen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
- (2012) Naga Chalasani et al. GASTROENTEROLOGY
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
- (2011) G. Vernon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008
- (2011) Zobair M. Younossi et al. Clinical Gastroenterology and Hepatology
- A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients
- (2010) R. Anty et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- (2010) Christopher D. Williams et al. GASTROENTEROLOGY
- Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection
- (2010) Brad Q. Starley et al. HEPATOLOGY
- Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease
- (2009) Y. YILMAZ ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study
- (2009) Ariel E. Feldstein et al. HEPATOLOGY
- A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH)
- (2008) Zobair M. Younossi et al. OBESITY SURGERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started